Genome-wide association studies in pharmacogenomics

Nat Rev Genet. 2010 Apr;11(4):241-6. doi: 10.1038/nrg2751.

Abstract

Genome-wide association (GWA) studies for pharmacogenomics-related traits are increasingly being performed to identify loci that affect either drug response or susceptibility to adverse drug reactions. Until now, only the largest effects have been detected, partly because of the challenges of obtaining large numbers of cases for pharmacogenomic studies. Since 2007, a range of pharmacogenomics GWA studies have been published that have identified several interesting and novel associations between drug responses or reactions and clinically relevant loci, showing the value of this approach.

Publication types

  • Review

MeSH terms

  • Anticoagulants / administration & dosage
  • Aryl Hydrocarbon Hydroxylases / genetics
  • Chemical and Drug Induced Liver Injury / genetics
  • Cytochrome P-450 CYP2C9
  • Drug-Related Side Effects and Adverse Reactions / genetics
  • Floxacillin / adverse effects
  • Genome-Wide Association Study / methods*
  • Genome-Wide Association Study / trends
  • Humans
  • Interferon-alpha / administration & dosage
  • Mixed Function Oxygenases / genetics
  • Muscular Diseases / chemically induced
  • Muscular Diseases / genetics
  • Pharmacogenetics / methods*
  • Pharmacogenetics / trends
  • Platelet Aggregation Inhibitors / administration & dosage
  • Simvastatin / adverse effects
  • Vitamin K Epoxide Reductases

Substances

  • Anticoagulants
  • Interferon-alpha
  • Platelet Aggregation Inhibitors
  • Floxacillin
  • Simvastatin
  • Mixed Function Oxygenases
  • CYP2C9 protein, human
  • Cytochrome P-450 CYP2C9
  • Aryl Hydrocarbon Hydroxylases
  • Vitamin K Epoxide Reductases